AbbVie Inc.

ABBV-N

NYSE:ABBV

92.67
2.64 (2.93%)
AbbVie is a pharmaceutical company that discovers, develops and markets both biopharmaceuticals and small molecule drugs. It originated in 2013 as a spin-off of Abbott Laboratories.
More at Wikipedia

Analysis and Opinions about ABBV-N

Signal
Opinion
Expert
PAST TOP PICK
PAST TOP PICK
August 27, 2014

(A Top Pick Sept 18/13. Up 20.17%.) Sold his holdings, but is now looking for an opportunity to get back in. Believes biotech and healthcare will be meaningful to society or move markets to change the world the way computers did.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
August 27, 2014

(A Top Pick Sept 18/13. Up 20.17%.) Sold his holdings, but is now looking for an opportunity to get back in. Believes biotech and healthcare will be meaningful to society or move markets to change the world the way computers did.

SELL
SELL
August 20, 2014

(Market Call Minute.) This is a spin off from Abbott Labs (ABT-N). What concerns him is that they own Humera, a great drug, but it is coming off patent in 2016 and represents about 65% of their business.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
August 20, 2014

(Market Call Minute.) This is a spin off from Abbott Labs (ABT-N). What concerns him is that they own Humera, a great drug, but it is coming off patent in 2016 and represents about 65% of their business.

PAST TOP PICK
PAST TOP PICK
April 7, 2014

(A Top Pick March 1/13. Up 38.65%.) Has been pretty volatile in the last little while. If it breaks down, it could go down to $48. Healthcare is still in a secular bull market, which is really positive. This is the place to be for the next 20 years.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
April 7, 2014

(A Top Pick March 1/13. Up 38.65%.) Has been pretty volatile in the last little while. If it breaks down, it could go down to $48. Healthcare is still in a secular bull market, which is really positive. This is the place to be for the next 20 years.

TOP PICK
TOP PICK
November 14, 2013

Has a fantastic mix of assets. Earnings have been fantastic. Long-term chart looks fantastic. Another big driver is that the whole healthcare space has come out of the woods. The next 10 years looks really good for the space.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
November 14, 2013

Has a fantastic mix of assets. Earnings have been fantastic. Long-term chart looks fantastic. Another big driver is that the whole healthcare space has come out of the woods. The next 10 years looks really good for the space.

TOP PICK
TOP PICK
September 18, 2013

Undervalued, experimental medicines is the cure for an ailing portfolio. Well-run company. Healthcare is in a secular bull market. He would wait for a pullback or a breakout. Yield of 3.38%.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
September 18, 2013

Undervalued, experimental medicines is the cure for an ailing portfolio. Well-run company. Healthcare is in a secular bull market. He would wait for a pullback or a breakout. Yield of 3.38%.

TOP PICK
TOP PICK
April 8, 2013

Healthcare is in a secular trend. This sector has the mother of all bases. Spun out of Abbot labs. He would add to this at $38/9. This is the second inning of healthcare across the board. You are getting a bit of a discount because of the spin out.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
April 8, 2013

Healthcare is in a secular trend. This sector has the mother of all bases. Spun out of Abbot labs. He would add to this at $38/9. This is the second inning of healthcare across the board. You are getting a bit of a discount because of the spin out.

TOP PICK
TOP PICK
March 1, 2013

Has a really good pipeline. Has a slight upward trend with a little bit of a channel. Feels the Humera drug will continue driving sales. Nice yield of 4.23%. Pharmaceuticals are in a really new bull market.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
March 1, 2013

Has a really good pipeline. Has a slight upward trend with a little bit of a channel. Feels the Humera drug will continue driving sales. Nice yield of 4.23%. Pharmaceuticals are in a really new bull market.

COMMENT
COMMENT
February 26, 2013

Abbott Labs (ABT-N) Split into 2 companies. This one has the pharmaceuticals. One drug accounts for 50% of their revenues and the patent comes off in 2016. Big, big risk. They are drastically looking to replace this drug. Generating huge margins. Huge amount of free cash flow. (See Top Picks.)

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
February 26, 2013

Abbott Labs (ABT-N) Split into 2 companies. This one has the pharmaceuticals. One drug accounts for 50% of their revenues and the patent comes off in 2016. Big, big risk. They are drastically looking to replace this drug. Generating huge margins. Huge amount of free cash flow. (See Top Picks.)

TOP PICK
TOP PICK
February 15, 2013

This was a spinoff from Abbott Labs (ABT-N). People are selling this because they don’t know what it is. His model price is $50, an upside of 37%. Yield of 4.3%.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
February 15, 2013

This was a spinoff from Abbott Labs (ABT-N). People are selling this because they don’t know what it is. His model price is $50, an upside of 37%. Yield of 4.3%.

DON'T BUY
DON'T BUY
January 10, 2013

Wouldn’t look at this one too closely because it is very concentrated. Their Humira drug makes up a large percentage of their total revenues and goes off patent in 2016.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
January 10, 2013

Wouldn’t look at this one too closely because it is very concentrated. Their Humira drug makes up a large percentage of their total revenues and goes off patent in 2016.

Showing 46 to 55 of 55 entries